Hypersensitivity. Discontinue use in patients w/ HLA-B* 507 allele. Pancreatitis; immune reactivation syndrome. Risk of virological failure; osteonecrosis; MI. Opportunistic infections & other complications of HIV infection. Periodic monitoring of LFT & HBV replication markers upon discontinuation in patients co-infected w/ HBV. Triple nucleoside therapy. Not recommended in combination of lamivudine w/ cladribine. Allergic reactions due to azo colouring agent. Not recommended in renal & moderate or severe hepatic impairment; preexisting liver dysfunction. Pregnancy & lactation. Mitochondrial dysfunction in HIV -ve infants exposed in utero
&/or post-natally to nucleoside analogues. Childn <25 kg. Elderly >65 yr.